BPCO, cambia l'approccio. Due broncodilatatori la nuova terapia standard | AZ Salute
Asthma & COPD Medications Chart - National Asthma Council Australia
effect of laBa/laMa versus laMa or laBa/ICs on safety outcomes | Download Table
Atti della Accademia Lancisiana - Numeri della Rivista
Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management | npj Primary Care Respiratory Medicine
ICS/LABA/LAMA per la BPCO è stata approvata in Europa • NCF
GlaxoSmithKline Is Focused on Maintaining Leadership in This Segment
GSK 렐바 엘립타 시장 점유율 40% 돌파 < 제약산업 < 제약·유통 < 기사본문 - 의학신문
Health Related Quality of Life | Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Jacob Plieth on X: "More on asthma. Interesting development - first time $NVS has disclosed LAMA/LABA/ICS triple $GSK $AZN $THRX http://t.co/0bAiw6Qbfa" / X
Contents Agenda Presenter biographies Presentations - ppt download
IMPACT Study Data | TRELEGY ELLIPTA (fluticasone furoate, umeclidinium & vilanterol)
Available iCS plus LABA combination products | Download Table
Farmacoutilizzazione della terapia inalatoria nella Medicina Generale italiana
Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD - ScienceDirect
FDA duyệt Trelegy (GSK), sau kết quả khả quan so sánh với combo 2 hoạt chất
Treatment patterns in English asthma patients initiating multiple inhaler triple therapy: a cohort study | European Respiratory Society
Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study - ScienceDirect
LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the d | COPD
Figure 2 from LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes | Semantic Scholar
Population-based study of LAMA monotherapy effectiveness compared with LABA/ LAMA as initial treatment for COPD in primary care | npj Primary Care Respiratory Medicine
How Will The New GSK Respiratory Portfolio Fare In 2017? (NYSE:GSK) | Seeking Alpha
Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study - ScienceDirect
Effectiveness of Treatment With Dual Bronchodilation (LABA/LAMA) Compared With Combination Therapy (LABA/ICS) for Patients With COPD: A Population-Based Study | Archivos de Bronconeumología
Mario Cazzola, ERS 2018 – Impact of ICS/LABA and LABA/LAMA on lung function and exacerbation of COPD - YouTube
